In addition, the Executive Board and Supervisory Board today decided to propose to the Annual General Meeting a resolution to increase the share capital from company funds by EUR 15,878,949.00 from the current EUR 5,292,983.00 by EUR 15,878,949.00 to EUR 21,171,932.00 by issuing new shares (§§ 207 et seq. of the AktG) by way of converting free reserves into share capital of the company. In doing so, the shareholders of the Company shall receive three (3) new shares for each one (1) existing share.
The capital increase from company funds will not result in any changes to the shareholders‘ participations in the company. If the proposed resolutions are accepted by the General Meeting and the amendments to the Articles of Association are entered in the Commercial Register, each shareholder will be credited with the corresponding number of new shares in his or her securities account. The higher number of shares and the resulting reduction in the share price should make the Company’s shares more liquid and even more attractive for investors.
The price of the Eckert & Ziegler share has risen continuously over the past few years. The aim of the increase in the share capital of Eckert & Ziegler AG from company funds by issuing new shares in a ratio of 1:3, to be proposed to the Annual General Meeting, is to make trading in the share more liquid and to make the share even more attractive for investors.
The complete figures for the FY 2019 and the forecast for the current FY 2020 will be published on 31 March 2020.
In view of the current situation (COVID-19), a postponement of the Annual General Meeting currently planned for 17 June 2020 cannot be excluded.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112